Navigation Links
HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
Date:5/29/2008

-Technology for quantitative profiling of protein biomarkers in tissue now available to investigators at DF/HCC member institutions through Brigham

and Women's Pathology Core Facility-

NEW HAVEN, Conn., May 29 /PRNewswire/ -- HistoRx, Inc., announced today that the pathology core facility at Brigham and Women's Hospital (BWH) will begin making the company's AQUA(R) technology for protein biomarker profiling available to the more than 900 Dana-Farber/Harvard Cancer Center (DF/HCC) scientists that are serviced by the facility. Brigham and Women's purchased a HistoRx PM-2000(TM) tissue analysis platform instrument, which incorporates the proprietary AQUA(R) technology, in 2005.

The pathology core facility at BWH is a service hub that provides state-of-the-art tissue-based tests and analysis to investigators at DF/HCC institutions, which include Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Children's Hospital Boston, Beth Israel Deaconess Hospital, and Massachusetts General Hospital. The core facility is using the AQUA(R) technology to identify and quantify protein biomarkers in tissue samples for researchers advancing studies on cancer diagnostics and drug development. Jon Aster, M.D., Ph.D., core facility director and Associate Professor in the Department of Pathology, and Scott Rodig, M.D., Ph.D., Assistant Professor in Pathology, both of BWH, will oversee the technology access expansion to the DF/HCC member institutions.

The PM-2000(TM) system, now in use at 12 leading cancer and pathology research centers through the HARP(TM) program (HistoRx Academic Research Program), enables the reliable measurement of protein biomarkers in tissue and tissue microarrays based on fluorescent immunohistochemical methods. Assays developed on the system may be used to better understand the origins of diseases as well as to aid in patient selection for clinical tri
'/>"/>

SOURCE HistoRx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
2. Favrille Announces Workforce Reduction
3. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
4. Genmab Announces 2008 First Quarter Results
5. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
6. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
7. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
8. WuXi PharmaTech Announces First Quarter 2008 Results
9. WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
10. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
11. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Charlotte, NC (PRWEB) October 24, 2014 ... high intensity focused ultrasound (HIFU) technology, announced that ... Carol, M.D. as Chief Executive Officer, President and ... new role Dr. Carol will take-on expanded responsibilities ... HIFU technology, as well as overseeing commercialization, manufacturing ...
(Date:10/25/2014)... JERUSALEM , October 24, 2014 ... a clinical-stage pharmaceutical company focused on the development of ... CEO, Nadav Kidron will present at FireRock ... ,FireRock Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, ... Building, New York City , ...
(Date:10/25/2014)... 2014 Investor-Edge has initiated coverage ... CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ... Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended on a positive note as the Dow Jones ...
(Date:10/22/2014)... 22, 2014 New test innovations will be ... diagnostic (IVD) test industry, especially as companies struggle with ... listed more than 25 testing innovations in important disease ... of IVD products. Kalorama details the new approaches its biennial ... for In Vitro Diagnostic Tests , 9th Edition ...
Breaking Biology Technology:SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3
... Inc. (Nasdaq:,BIOD) today reported financial results for its second quarter ... $9.6 million or $0.43 per share., "We remain on ... and Chairman of Biodel. "The last patient visits for,both pivotal ... We,expect to announce top line data late in the third ...
... Pennsylvania and OXFORD, England, May 9 ,EUSA Pharma ... oncology, pain control and critical care, today announced ... following the,approval of Cytogen,s shareholders at a special ... of the acquisition agreement, Cytogen shareholders will,receive $0.62 ...
... Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that the ... 2008 Healthcare Conference on May 14, 2008 at 5:20 ... Seasons Hotel in Las,Vegas, Nevada. Dominic P. Behan, Ph.D., ... to provide an overview of the,company, including its clinical ...
Cached Biology Technology:Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 2Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 3Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 4Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 5Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 6Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 7Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 8Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 9EUSA Pharma Completes Acquisition Of Cytogen Corporation 2EUSA Pharma Completes Acquisition Of Cytogen Corporation 3Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 2Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 3
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
(Date:10/16/2014)... Syncytial Virus causes severe respiratory tract infections and ... year. Scientists at VIB and Ghent University have ... counteract this common virus infection. , Xavier ... that paves the way for the development of ... virus that causes suffering in numerous small children ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... In recent years, the possible applications for double-walled ... those working on developing renewable energy technologies. These ... thin enough to be transparent, yet can still ... advanced solar panels, sensors and a host of ...
... for Glycomics in collaboration with colleagues at the ... to identifying a broad spectrum treatment for the ... These highly-infectious viruses are the leading cause of ... of hospitalisations in the developed world, and hundreds ...
... Dec. 23, 2008 -- The reproductive spores of many ... to new research by mycologists and applied mathematicians at ... this week in the Proceedings of the National ... fungal spores is within one percent of the absolute ...
Cached Biology News:Researchers find chink in the armor of viral 'tummy bug' 2In many fungi, reproductive spores are remarkably aerodynamic 2
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
... T4 DNA Ligase catalyzes the joining of ... and the 3´-hydroxyl groups of adjacent nucleotides ... (1). The enzyme has also been shown ... either a DNA or RNA strand in ...
... Chain MAP1A and MAP1B are microtubule-associated proteins ... components of the cytoskeleton. MAP1A and MAP1B each ... light chain subunits. The protein encoded by this ... and can associate with either MAP1A or MAP1B. ...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Biology Products: